Stephen N Crooke1, Iana H Haralambieva1, Diane E Grill2, Inna G Ovsyannikova1, Richard B Kennedy1, Gregory A Poland3. 1. Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. 2. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905, USA. 3. Mayo Clinic Vaccine Research Group, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: poland.gregory@mayo.edu.
Abstract
BACKGROUND: Although the administration of the measles-mumps-rubella (MMR) vaccine has been widespread in the United States for decades, gaps in vaccine coverage still persist for various reasons. The maintenance of herd immunity against rubella virus (RV) is important to controlling the spread and resurgence of rubella and congenital rubella syndrome. METHODS: In this study, we sought to assess the seroprevalence of RV-specific antibodies in an adult population from a defined geographic area in Olmsted County, MN, and the surrounding municipalities, with relatively high vaccine coverage and no documented evidence of circulating RV in the past 24 years. Rubella-specific IgG antibodies were measured by ELISA in a large set of serum samples (n = 1393) obtained from the Mayo Clinic Biobank. This cohort was 80.2% female and ranged from 20 to 44 years of age. RESULTS: In total, 97.8% of subjects were seropositive for rubella-specific IgG antibodies, with a median titer of 40.56 IU/mL, suggesting a high degree of immunization; however, 2.2% of subjects were found to be seronegative. Interestingly, 25.1% of subjects were seropositive but had titers lower than 25 IU/mL, indicating either a population of low responders or individuals that could potentially be at risk of waning immunity. No significant associations or differences were found between RV-specific titers and demographic variables such as age, sex, or body mass index (BMI). CONCLUSIONS: A high rate of seropositivity for rubella was found among this young adult cohort, but a significant percent of the cohort had lower titers that may indicate poor initial vaccine response and potential risk if their antibody titers decline.
BACKGROUND: Although the administration of the measles-mumps-rubella (MMR) vaccine has been widespread in the United States for decades, gaps in vaccine coverage still persist for various reasons. The maintenance of herd immunity against rubella virus (RV) is important to controlling the spread and resurgence of rubella and congenital rubella syndrome. METHODS: In this study, we sought to assess the seroprevalence of RV-specific antibodies in an adult population from a defined geographic area in Olmsted County, MN, and the surrounding municipalities, with relatively high vaccine coverage and no documented evidence of circulating RV in the past 24 years. Rubella-specific IgG antibodies were measured by ELISA in a large set of serum samples (n = 1393) obtained from the Mayo Clinic Biobank. This cohort was 80.2% female and ranged from 20 to 44 years of age. RESULTS: In total, 97.8% of subjects were seropositive for rubella-specific IgG antibodies, with a median titer of 40.56 IU/mL, suggesting a high degree of immunization; however, 2.2% of subjects were found to be seronegative. Interestingly, 25.1% of subjects were seropositive but had titers lower than 25 IU/mL, indicating either a population of low responders or individuals that could potentially be at risk of waning immunity. No significant associations or differences were found between RV-specific titers and demographic variables such as age, sex, or body mass index (BMI). CONCLUSIONS: A high rate of seropositivity for rubella was found among this young adult cohort, but a significant percent of the cohort had lower titers that may indicate poor initial vaccine response and potential risk if their antibody titers decline.
Authors: Fabio Lievano; Susan A Galea; Michele Thornton; Richard T Wiedmann; Susan B Manoff; Trung N Tran; Manisha A Amin; Margaret M Seminack; Kristen A Vagie; Adrian Dana; Stanley A Plotkin Journal: Vaccine Date: 2012-09-07 Impact factor: 3.641
Authors: Emily A Voigt; Iana H Haralambieva; Beth L Larrabee; Richard B Kennedy; Inna G Ovsyannikova; Daniel J Schaid; Gregory A Poland Journal: J Infect Dis Date: 2018-01-30 Impact factor: 5.226
Authors: Nathaniel D Lambert; V Shane Pankratz; Beth R Larrabee; Adaeze Ogee-Nwankwo; Min-hsin Chen; Joseph P Icenogle; Gregory A Poland Journal: Clin Vaccine Immunol Date: 2014-01-03
Authors: Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; Krista M Goergen; Diane E Grill; Min-Hsin Chen; Lijuan Hao; Joseph Icenogle; Gregory A Poland Journal: Vaccine Date: 2019-11-12 Impact factor: 3.641
Authors: Stephen N Crooke; Marguerite M Riggenbach; Inna G Ovsyannikova; Nathaniel D Warner; Min-Hsin Chen; Lijuan Hao; Joseph P Icenogle; Gregory A Poland; Richard B Kennedy Journal: Vaccine Date: 2020-11-12 Impact factor: 3.641
Authors: Stephen N Crooke; Inna G Ovsyannikova; Richard B Kennedy; Nathaniel D Warner; Gregory A Poland Journal: Vaccine Date: 2020-11-04 Impact factor: 3.641
Authors: Luca Coppeta; Cristiana Ferrari; Ilaria Iannuzzi; Iacopo D'Alessandro; Ottavia Balbi; Antonio Pietroiusti; Marco Trabucco Aurilio Journal: Int J Environ Res Public Health Date: 2020-10-30 Impact factor: 3.390